Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade

Description of Zanolimumab Biosimilar - Anti-CD4 mAb - Research Grade

Introduction to Zanolimumab Biosimilar – Anti-CD4 mAb – Research Grade

Zanolimumab Biosimilar is a novel therapeutic antibody that targets the CD4 protein, a key player in the immune system. This biosimilar is designed to mimic the structure and activity of the original antibody, providing a cost-effective and accessible treatment option for various diseases. In this article, we will explore the structure, activity, and potential applications of Zanolimumab Biosimilar in detail.

Structure of Zanolimumab Biosimilar

Zanolimumab Biosimilar is a monoclonal antibody (mAb) that is produced by recombinant DNA technology. It is a humanized IgG1 antibody, meaning that it has been engineered to have a human-like structure to reduce the risk of immune reactions. The antibody is composed of two heavy chains and two light chains, each with a unique amino acid sequence. The heavy chains are responsible for binding to the CD4 protein, while the light chains provide stability to the overall structure of the antibody.

Activity of Zanolimumab Biosimilar

Zanolimumab Biosimilar works by binding to the CD4 protein, which is found on the surface of certain immune cells, including T-helper cells. This binding prevents the CD4 protein from interacting with other immune cells, thereby inhibiting the immune response. This activity is particularly beneficial in diseases where the immune system is overactive, such as autoimmune disorders and inflammatory conditions.

Title: Applications of Zanolimumab Biosimilar

Zanolimumab Biosimilar has shown promising results in preclinical studies for various diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. In rheumatoid arthritis, the antibody has been shown to reduce inflammation and joint damage by inhibiting the activity of T-helper cells. In psoriasis, Zanolimumab Biosimilar has been found to improve skin lesions and reduce the severity of symptoms by targeting the immune cells responsible for the disease. In multiple sclerosis, the antibody has been shown to delay disease progression by modulating the immune response.

Advantages of Zanolimumab Biosimilar

Zanolimumab Biosimilar offers several advantages over the original antibody, including lower production costs, increased accessibility, and improved safety profile. As a biosimilar, it is produced using the same manufacturing process as the original antibody, but at a lower cost, making it more affordable for patients. This also allows for increased accessibility to treatment for patients in need. Furthermore, the humanized structure of Zanolimumab Biosimilar reduces the risk of immune reactions, making it a safer option for patients.

Conclusion

In conclusion, Zanolimumab Biosimilar is a promising therapeutic option for various diseases that target the CD4 protein. Its unique structure and activity make it an effective treatment for conditions where the immune system is overactive. With its lower production costs and improved safety profile, Zanolimumab Biosimilar has the potential to provide accessible and affordable treatment for patients in need. Further clinical trials and studies are needed to fully evaluate the efficacy and safety of this biosimilar, but it holds great promise in the field of immunotherapy.

Zanolimumab Biosimilar - Anti-CD4 mAb binds to Human CD4 in indirect ELISA Assay

Immobilized CD4 Protein - T-cell surface glycoprotein CD4(CD4) (cat. No. PX-P4702) at 0.5µg/mL (100µL/well) can bind Zanolimumab Biosimilar - Anti-CD4 mAb (cat. No. PX-TA1152) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 3.124M.

Zanolimumab Biosimilar - Anti-CD4 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.